Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer

Breast Cancer Clinical Trial

Official title:

A Randomized, Placebo Controlled Trial Of Zoledronic Acid For The Prevention Of Bone Loss In Premenopausal Women With Early Stage Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00049452
• Other study ID #: CDR0000258105
• Secondary ID: CPMC-IRB-14069NC
• Status: Completed
• Phase: Phase 3
• First received: November 12, 2002
• Last updated: January 3, 2014
• Start date: December 2001
• Est. completion date: August 2008

Study information

• Verified date: April 2007
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

RATIONALE: It is not yet known whether zoledronate is effective in preventing bone loss in premenopausal women who are receiving adjuvant chemotherapy after undergoing surgery for early stage breast cancer.

PURPOSE: Randomized phase III trial to determine the effectiveness of zoledronate in preventing bone loss in premenopausal women who are receiving chemotherapy after surgery for early stage breast cancer.

Description:

OBJECTIVES:

• Compare the changes in bone mineral density (BMD) and bone turnover that occur in premenopausal women with resected early stage breast cancer during and after 6 months of adjuvant chemotherapy.

• Determine the factors that predict bone loss during chemotherapy, particularly induction of amenorrhea, type of chemotherapeutic regimen, glucocorticoid exposure, and baseline BMD, in these patients.

• Determine whether zoledronate prevents bone loss in these patients when given during and after adjuvant chemotherapy.

• Determine the effect of zoledronate on markers of bone turnover in these patients during and after adjuvant chemotherapy.

• Determine whether the effect on markers of bone turnover predicts response to zoledronate in these patients.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to estrogen receptor status (positive vs negative), progesterone receptor status (positive vs negative), and adjuvant chemotherapy regimen. Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients receive zoledronate IV over 15 minutes on day 1.

• Arm II: Patients receive placebo IV over 15 minutes on day 1. In both arms, treatment repeats every 3 months for up to 4 courses in the absence of disease progression. Patients also receive calcium and cholecalciferol (vitamin D) supplements daily.

Quality of life is assessed at baseline and at 6 and 12 months.

Patients are followed at 1 year.

PROJECTED ACCRUAL: A total of 120 patients (60 per treatment arm) will be accrued for this study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: August 2008
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 50 Years

Eligibility

DISEASE CHARACTERISTICS:

• Diagnosis of localized breast cancer

• Stage I or II (T1-3, N0-2, M0)

• Planned adjuvant chemotherapy (after surgery) of at least 6 months in duration

• Hormone receptor status:

• Estrogen receptor and progesterone receptor status known

PATIENT CHARACTERISTICS:

Age

• 18 to 50

Sex

• Female

Menopausal status

• Premenopausal or perimenopausal

Performance status

• Not specified

Life expectancy

• Not specified

Hematopoietic

• Not specified

Hepatic

• Not specified

Renal

• Creatinine less than 2 mg/dL

Other

• No T score of less than 2.0 on bone mineral density (BMD)

• No fragility fracture

• No lumbar spine anatomy that would preclude accurate BMD measurement of a minimum of 3 lumbar vertebrae

• Not pregnant

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• See Disease Characteristics

Endocrine therapy

• Not specified

Radiotherapy

• No concurrent radiotherapy

Surgery

• See Disease Characteristics

Other

• At least 1 month since prior calcitonin

• At least 12 months since prior bisphosphonates given for more than 1 month duration

• No concurrent fluoride therapy (10 mg/day or more)

• No concurrent enrollment in another experimental drug study

Study Design

Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Osteoporosis

Intervention

Drug:
• zoledronic acid

Locations

Country	Name	City	State
United States	Herbert Irving Comprehensive Cancer Center at Columbia University	New York	New York
United States	Valley Hospital - Paramus	Paramus	New Jersey
United States	Carl and Dorothy Bennett Cancer Center at Stamford Hospital	Stamford	Connecticut

Sponsors (2)

Lead Sponsor	Collaborator
Herbert Irving Comprehensive Cancer Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (2)

Hershman DL, McMahon DJ, Crew KD, Cremers S, Irani D, Cucchiara G, Brafman L, Shane E. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2008 Oct 10;26(29):4739-45. doi: — View Citation

Hershman DL, McMahon DJ, Crew KD, Shao T, Cremers S, Brafman L, Awad D, Shane E. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J Clin Endocrinol — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in lumbar spine bone mineral density (BMD) at 6 months
Secondary	Changes in lumbar spine BMD at 12 and 24 months
Secondary	Total hip and femoral neck BMD at 6, 12, and 24 months
Secondary	Serum markers of bone turnover (osteocalcin, bone-specific alkaline phosphatase, and cross-linked C-telopeptide of type 1 collagen levels) measured every 6 weeks for 6 months, and at 9 and 12 months
Secondary	Quality of life as measured by the Short Form-36 instrument at baseline, and at 6 and 12 months
Secondary	Treatment costs